Prevention of death in COPD [1]

New England Journal of Medicine

Volumn 356, Issue 21, 2007, Pages 2211-2214

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE; SALMETEROL; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE COURSE; DRUG MECHANISM; HUMAN; LETTER; LUNG FUNCTION; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; NOTE; DISEASE EXACERBATION; DRUG EFFECT; FACTORIAL ANALYSIS; HEALTH STATUS; THERAPY EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; FACTOR ANALYSIS, STATISTICAL;

EID: 34347340694     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070783     Document Type: Letter

References (5)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
2. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7.
3. Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006;130:640-6.
4. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9.
5. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006;129:151-5.